Home    Back

Rvt-1401    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
11Myasthenia1
61Autoimmune hemolytic anemia4

11. Myasthenia    [ 226 clinical trials,   172 drugs,   (DrugBank: 45 drugs),   43 drug target genes,   118 drug target pathways]
Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 226 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03863080
(ClinicalTrials.gov)		May 21, 201920/2/2019A Study of RVT-1401 in Myasthenia Gravis (MG) PatientsA Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis PatientsMyasthenia GravisDrug: RVT-1401;Drug: PlaceboImmunovant Sciences GmbHNULLRecruiting18 YearsN/AAll21Phase 2United States;Canada

61. Autoimmune hemolytic anemia    [ 90 clinical trials,   72 drugs,   (DrugBank: 23 drugs),   19 drug target genes,   147 drug target pathways]
Searched query = "Autoimmune hemolytic anemia", "AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "MAIHA", "Evans syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 90 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2019-003924-19-HU
(EUCTR)		07/10/202017/08/2020Non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic AnemiaA Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia - ASCEND-WAIHA Warm Autoimmune Hemolytic Anemia
MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Name: RVT-1401
Product Code: RVT-1401
INN or Proposed INN: RVT-1401
Other descriptive name: RVT-1401		Immunovant Sciences GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		16Phase 2United States;Hungary;Thailand;Spain;Israel;United Kingdom;Korea, Republic of
2NCT04253236
(ClinicalTrials.gov)		August 11, 202021/1/2020To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic AnemiaWarm Autoimmune Hemolytic AnemiaDrug: RVT-1401 680 mg/weekly;Drug: RVT-1401 340 mg/weeklyImmunovant Sciences GmbHNULLRecruiting18 YearsN/AAll16Phase 2United States;Israel;Korea, Republic of;Spain;Thailand;United Kingdom
3EUCTR2019-003924-19-ES
(EUCTR)		25/05/202014/01/2020Non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic AnemiaA Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia - ASCEND-WAIHA Warm Autoimmune Hemolytic Anemia
MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Name: RVT-1401
Product Code: RVT-1401
INN or Proposed INN: RVT-1401
Other descriptive name: RVT-1401		Immunovant Sciences GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		16Phase 2United States;Hungary;Thailand;Spain;Romania;Israel;United Kingdom;Korea, Republic of
4EUCTR2019-003924-19-GB
(EUCTR)		26/02/202013/03/2020Non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic AnemiaA Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia - ASCEND-WAIHA Warm Autoimmune Hemolytic Anemia
MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Name: RVT-1401
Product Code: RVT-1401
INN or Proposed INN: RVT-1401
Other descriptive name: RVT-1401		Immunovant Sciences GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		16Phase 2United States;Thailand;Spain;Romania;Israel;United Kingdom;Korea, Republic of

Back to top